Back to Browse Journals » Cancer Management and Research » Volume 4

Carmustine enhances the anticancer activity of selenite in androgen-independent prostate cancer cells

Authors Thamilselvan V, Menon M, Thamilselvan S

Published Date November 2012 Volume 2012:4 Pages 383—395

DOI http://dx.doi.org/10.2147/CMAR.S38022

Received 12 September 2012, Accepted 12 October 2012, Published 9 November 2012

Vijayalakshmi Thamilselvan, Mani Menon, Sivagnanam Thamilselvan

Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI, USA

Abstract: Apoptosis is one of the major mechanisms targeted in the development of therapies against various cancers, including prostate cancer. Resistance to chemotherapy poses a significant problem for the effective treatment of androgen-independent (hormone-refractory) prostate cancer. Although high concentrations of sodium selenite exert strong anticarcinogenic effects in several cell culture systems and animal models, the therapeutic potential of selenite in patients with advanced or metastatic prostate cancer is extremely limited by the genotoxicity of high-dose selenite. We examined the ability of nontoxic concentrations of selenite to promote apoptosis and inhibit proliferation in carmustine-sensitized androgen-independent human prostate cancer cells. Androgen-dependent LNCaP cells exhibited a significant decrease in cell viability when exposed to nontoxic concentrations of selenite, whereas androgen-independent PC-3 and DU145 cells showed a significant decrease in cell viability only at higher concentrations. Treatment of PC-3 cells with a combination of nontoxic selenite and carmustine resulted in greater increases in cytotoxicity, reactive oxygen species generation, growth inhibition, apoptosis, and DNA double-strand breaks, with concomitant decreases in DNA synthesis, glutathione, glutathione reductase, and antiapoptotic proteins. Combination treatment with carmustine and selenite triggered caspase-dependent apoptosis in PC-3 cells, which was not apparent when these cells were treated with selenite or carmustine alone. Genotoxicity in normal prostate epithelial cells was completely absent in the combination treatment of carmustine and selenite. In addition, carmustine decreased the induction of DNA double strand breaks by high-dose selenite in normal prostate epithelial cells. This is the first study to demonstrate that a nontoxic dose of selenite, in combination with carmustine, significantly induces apoptosis and growth inhibition in androgen-independent prostate cancer cells without causing undesirable genotoxicity in normal prostate epithelial cells, suggesting that this combination therapy may be a promising therapeutic approach in the treatment of patients with metastatic hormone-refractory prostate cancer.

Keywords: apoptosis, glutathione, glutathione reductase, oxidative stress, DNA damage, genotoxicity, combination therapy

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

An extract of the medicinal plant Artemisia annua modulates production of inflammatory markers in activated neutrophils

Hunt S, Yoshida M, Davis CEJ, Greenhill NS, Davis PF

Journal of Inflammation Research 2015, 8:9-14

Published Date: 14 January 2015

CANTAB object recognition and language tests to detect aging cognitive decline: an exploratory comparative study

Cabral Soares F, Oliveira TCG, Macedo LDD, Tomás AM, Picanço-Diniz DLW, Bento-Torres J, Bento-Torres NVO, Picanço-Diniz CW

Clinical Interventions in Aging 2015, 10:37-48

Published Date: 19 December 2014

Lebrikizumab in the personalized management of asthma

Thomson NC, Patel M, Smith AD

Biologics: Targets and Therapy 2012, 6:329-335

Published Date: 14 September 2012

Behavioral cues to expand a pain model of the cognitively impaired elderly in long-term care

Burfield AH, Wan TTH, Sole ML, Cooper JW

Clinical Interventions in Aging 2012, 7:207-223

Published Date: 2 July 2012

DataGenno: building a new tool to bridge molecular and clinical genetics

Fabricio F Costa, Luciano S Foly, Marcelo P Coutinho

The Application of Clinical Genetics 2011, 4:45-54

Published Date: 18 March 2011

Cardioprotective and β-adrenoceptor antagonistic activity of a newly synthesized aryloxypropanolamine derivative PP-36

Lokesh K Bhatt, Jyotika Bansal, Poonam Piplani, SL Bodhankar, A Veeranjaneyulu

Journal of Experimental Pharmacology 2010, 2:37-45

Published Date: 15 February 2010